+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
New

Mpox Diagnostics - Global Strategic Business Report

  • PDF Icon

    Report

  • 268 Pages
  • July 2025
  • Region: Global
  • Global Industry Analysts, Inc
  • ID: 6106093
The global market for Mpox Diagnostics was estimated at US$1.9 Billion in 2024 and is projected to reach US$2.2 Billion by 2030, growing at a CAGR of 2.7% from 2024 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions. The report includes the most recent global tariff developments and how they impact the Mpox Diagnostics market.

Global Mpox Diagnostics Market - Key Trends & Drivers Summarized

Why Is There Renewed Focus on Diagnostic Solutions for Mpox?

Mpox diagnostics have gained renewed urgency due to changing patterns in disease outbreaks, increasing global surveillance efforts, and a shift in case detection priorities. Earlier, mpox was largely endemic to specific regions, but recent cross-border transmission has made timely diagnosis a public health priority. Diagnosis plays a central role in early case isolation, outbreak tracking, and contact tracing. To ensure speed and accuracy, diagnostic tools now focus on lesion-based sampling rather than traditional serological approaches.

Laboratory testing continues to rely primarily on nucleic acid amplification methods. These techniques detect the presence of viral DNA in skin lesions and scabs. Testing accuracy is highest when samples are collected from active lesions, avoiding potential variability in viral load from blood samples. Focus has shifted toward tools that allow rapid, reliable, and decentralized testing, particularly in regions with limited access to advanced laboratory infrastructure. Simplification of sample collection and faster processing times are increasingly important design factors for new diagnostic platforms.

What Makes PCR-Based Testing the Benchmark in Current Practice?

PCR-based testing remains the foundation for accurate mpox diagnosis. This method is highly sensitive and specific, detecting even low quantities of viral DNA. Real-time PCR assays are currently the most trusted platform used in clinical settings and public health laboratories. These tests target specific regions of the mpox virus genome, allowing differentiation between clades and confirmation of infection status. Several types of PCR systems exist, ranging from lab-based analyzers to portable, cartridge-based units designed for point-of-care use.

New molecular diagnostic platforms are emerging to improve access and reduce turnaround times. Some allow testing in under one hour, supporting faster decision-making in outbreak settings. These systems are particularly useful where rapid patient triage and isolation are needed. In addition to centralized testing, portable molecular platforms are gaining relevance for use in field hospitals, border entry points, and mobile health units. Emphasis remains on operational simplicity, minimal technical training, and compatibility with existing healthcare workflows.

Why Have Rapid Antigen Tests Failed to Meet Diagnostic Standards?

Antigen-based rapid diagnostic tests have not yet proven reliable for mpox detection. While some show high specificity, their sensitivity is consistently low. Most antigen tests struggle to detect lower viral loads, especially in early or healing stages of infection. Their inability to detect asymptomatic or pre-symptomatic cases limits their use in surveillance or early response. This limitation restricts their role to supplementary screening rather than standalone diagnosis. Due to these constraints, health authorities do not currently endorse these tests for clinical use.

In response to these gaps, development efforts are shifting toward improved molecular tools and novel detection technologies. Some diagnostic tools now combine molecular detection with digital readouts or remote monitoring features. Experimental systems using AI-assisted image recognition to assess lesion photographs are also being evaluated. These tools aim to support diagnosis in remote locations where laboratory facilities are unavailable. However, such systems require further clinical validation before they can be used widely.

What Factors Are Driving Growth in the Mpox Diagnostics Market?

Growth in the mpox diagnostics market is driven by several factors. Rising frequency of outbreaks and their geographic spread has increased the demand for faster detection tools. Expanded use of point-of-care PCR devices is helping reduce testing delays in rural and low-resource settings. Integration of molecular diagnostics into outbreak response kits is enabling early containment. Increased investment in portable platforms that operate without extensive laboratory infrastructure is encouraging market participation from new manufacturers.

Greater emphasis on decentralized testing and mobile diagnostics is aligning with public health goals in developing countries. Uptake of digital health tools that link test results with surveillance databases is also contributing to efficient outbreak management. Growing need for differential diagnosis due to overlapping symptoms with other skin or febrile illnesses is raising the importance of high-specificity assays. Ongoing product approvals and regulatory guidance for emergency use of new diagnostic platforms continue to support product innovation and regional accessibility.

Scope Of Study:

The report analyzes the Mpox Diagnostics market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments: Diagnostic Test (Antigen Detection Test, Molecular Test); Sample (Urine Sample, Whole Blood Sample, Skin Lesion Specimen Sample)

Geographic Regions/Countries: World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Key Insights:

  • Market Growth: Understand the significant growth trajectory of the Antigen Detection Test segment, which is expected to reach US$1.5 Billion by 2030 with a CAGR of a 2.1%. The Molecular Test segment is also set to grow at 4.0% CAGR over the analysis period.
  • Regional Analysis: Gain insights into the U.S. market, estimated at $515.4 Million in 2024, and China, forecasted to grow at an impressive 5.0% CAGR to reach $426.1 Million by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.

Why You Should Buy This Report:

  • Detailed Market Analysis: Access a thorough analysis of the Global Mpox Diagnostics Market, covering all major geographic regions and market segments.
  • Competitive Insights: Get an overview of the competitive landscape, including the market presence of major players across different geographies.
  • Future Trends and Drivers: Understand the key trends and drivers shaping the future of the Global Mpox Diagnostics Market.
  • Actionable Insights: Benefit from actionable insights that can help you identify new revenue opportunities and make strategic business decisions.

Key Questions Answered:

  • How is the Global Mpox Diagnostics Market expected to evolve by 2030?
  • What are the main drivers and restraints affecting the market?
  • Which market segments will grow the most over the forecast period?
  • How will market shares for different regions and segments change by 2030?
  • Who are the leading players in the market, and what are their prospects?

Report Features:

  • Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2024 to 2030.
  • In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
  • Company Profiles: Coverage of players such as Abbott Laboratories, ACON Biotech (Hangzhou), Altona Diagnostics GmbH, Bio-Rad Laboratories, Inc., bioMérieux and more.
  • Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.

Some of the 34 companies featured in this Mpox Diagnostics market report include:

  • Abbott Laboratories
  • ACON Biotech (Hangzhou)
  • Altona Diagnostics GmbH
  • Bio-Rad Laboratories, Inc.
  • bioMérieux
  • Cepheid (Danaher Corporation)
  • Creative Biogene Inc.
  • DiaSorin S.p.A.
  • Hologic, Inc.
  • Labcorp
  • Mayo Clinic Laboratories
  • Meridian Bioscience
  • OraSure Technologies
  • PerkinElmer Inc.
  • Pfizer (Alinity™ m MPXV assay)
  • Qiagen N.V.
  • Quidel Corporation
  • Roche Diagnostics
  • Siemens Healthineers
  • Thermo Fisher Scientific Inc.
  • Quest Diagnostics

This edition integrates the latest global trade and economic shifts as of June 2025 into comprehensive market analysis. Key updates include:

  • Tariff and Trade Impact: Insights into global tariff negotiations across 180+ countries, with analysis of supply chain turbulence, sourcing disruptions, and geographic realignment. Special focus on 2025 as a pivotal year for trade tensions, including updated perspectives on the Trump-era tariffs.
  • Adjusted Forecasts and Analytics: Revised global and regional market forecasts through 2030, incorporating tariff effects, economic uncertainty, and structural changes in globalization. Includes segmentation by product, technology, type, material, distribution channel, application, and end-use, with historical analysis since 2015.
  • Strategic Market Dynamics: Evaluation of revised market prospects, regional outlooks, and key economic indicators such as population and urbanization trends.
  • Innovation & Technology Trends: Latest developments in product and process innovation, emerging technologies, and key industry drivers shaping the competitive landscape.
  • Competitive Intelligence: Updated global market share estimates for 2025, competitive positioning of major players (Strong/Active/Niche/Trivial), and refined focus on leading global brands and core players.
  • Expert Insight & Commentary: Strategic analysis from economists, trade experts, and domain specialists to contextualize market shifts and identify emerging opportunities.
  • Complimentary Update: Buyers receive a free July 2025 update with finalized tariff impacts, new trade agreement effects, revised projections, and expanded country-level coverage.

Table of Contents

I. METHODOLOGYII. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
  • Influencer Market Insights
  • World Market Trajectories
  • Tariff Impact on Global Supply Chain Patterns
  • Mpox Diagnostics - Global Key Competitors Percentage Market Share in 2025 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
  • Rising Global Incidence of Mpox Infections Spurs Demand for Rapid and Accurate Diagnostic Solutions
  • Government Surveillance Programs and Outbreak Preparedness Plans Drive Adoption of Diagnostic Testing
  • Technological Advancements in Point-of-Care Testing Strengthen Accessibility in Resource-Limited Settings
  • Integration of PCR and Isothermal Amplification Methods Propels Market for Molecular Mpox Diagnostics
  • Public Health Emergency Declarations Throw Spotlight on Fast-Tracking of Diagnostic Product Approvals
  • Expansion of Travel Screening and Quarantine Protocols Generates Demand for Portable Test Kits
  • Increasing Role of Central Laboratories in Outbreak Control Sustains Market for High-Throughput Systems
  • Demand for Cost-Effective Testing Solutions in Developing Nations Fuels Adoption of Lateral Flow Assays
  • Healthcare Worker Safety Protocols Drive Investment in Biosafe Sample Collection and Handling Tools
  • Growth in Zoonotic Disease Surveillance Expands Market Opportunity for Cross-Species Diagnostic Platforms
4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Mpox Diagnostics Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030
  • TABLE 2: World Recent Past, Current & Future Analysis for Mpox Diagnostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 3: World Historic Review for Mpox Diagnostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 4: World 16-Year Perspective for Mpox Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2025 & 2030
  • TABLE 5: World Recent Past, Current & Future Analysis for Antigen Detection Test by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 6: World Historic Review for Antigen Detection Test by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 7: World 16-Year Perspective for Antigen Detection Test by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 8: World Recent Past, Current & Future Analysis for Molecular Test by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 9: World Historic Review for Molecular Test by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 10: World 16-Year Perspective for Molecular Test by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 11: World Recent Past, Current & Future Analysis for Urine Sample by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 12: World Historic Review for Urine Sample by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 13: World 16-Year Perspective for Urine Sample by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 14: World Recent Past, Current & Future Analysis for Whole Blood Sample by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 15: World Historic Review for Whole Blood Sample by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 16: World 16-Year Perspective for Whole Blood Sample by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 17: World Recent Past, Current & Future Analysis for Skin Lesion Specimen Sample by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 18: World Historic Review for Skin Lesion Specimen Sample by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 19: World 16-Year Perspective for Skin Lesion Specimen Sample by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
III. MARKET ANALYSIS
UNITED STATES
  • Mpox Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
  • TABLE 20: USA Recent Past, Current & Future Analysis for Mpox Diagnostics by Diagnostic Test - Antigen Detection Test and Molecular Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 21: USA Historic Review for Mpox Diagnostics by Diagnostic Test - Antigen Detection Test and Molecular Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 22: USA 16-Year Perspective for Mpox Diagnostics by Diagnostic Test - Percentage Breakdown of Value Sales for Antigen Detection Test and Molecular Test for the Years 2014, 2025 & 2030
  • TABLE 23: USA Recent Past, Current & Future Analysis for Mpox Diagnostics by Sample - Urine Sample, Whole Blood Sample and Skin Lesion Specimen Sample - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 24: USA Historic Review for Mpox Diagnostics by Sample - Urine Sample, Whole Blood Sample and Skin Lesion Specimen Sample Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 25: USA 16-Year Perspective for Mpox Diagnostics by Sample - Percentage Breakdown of Value Sales for Urine Sample, Whole Blood Sample and Skin Lesion Specimen Sample for the Years 2014, 2025 & 2030
CANADA
  • TABLE 26: Canada Recent Past, Current & Future Analysis for Mpox Diagnostics by Diagnostic Test - Antigen Detection Test and Molecular Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 27: Canada Historic Review for Mpox Diagnostics by Diagnostic Test - Antigen Detection Test and Molecular Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 28: Canada 16-Year Perspective for Mpox Diagnostics by Diagnostic Test - Percentage Breakdown of Value Sales for Antigen Detection Test and Molecular Test for the Years 2014, 2025 & 2030
  • TABLE 29: Canada Recent Past, Current & Future Analysis for Mpox Diagnostics by Sample - Urine Sample, Whole Blood Sample and Skin Lesion Specimen Sample - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 30: Canada Historic Review for Mpox Diagnostics by Sample - Urine Sample, Whole Blood Sample and Skin Lesion Specimen Sample Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 31: Canada 16-Year Perspective for Mpox Diagnostics by Sample - Percentage Breakdown of Value Sales for Urine Sample, Whole Blood Sample and Skin Lesion Specimen Sample for the Years 2014, 2025 & 2030
JAPAN
  • Mpox Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
  • TABLE 32: Japan Recent Past, Current & Future Analysis for Mpox Diagnostics by Diagnostic Test - Antigen Detection Test and Molecular Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 33: Japan Historic Review for Mpox Diagnostics by Diagnostic Test - Antigen Detection Test and Molecular Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 34: Japan 16-Year Perspective for Mpox Diagnostics by Diagnostic Test - Percentage Breakdown of Value Sales for Antigen Detection Test and Molecular Test for the Years 2014, 2025 & 2030
  • TABLE 35: Japan Recent Past, Current & Future Analysis for Mpox Diagnostics by Sample - Urine Sample, Whole Blood Sample and Skin Lesion Specimen Sample - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 36: Japan Historic Review for Mpox Diagnostics by Sample - Urine Sample, Whole Blood Sample and Skin Lesion Specimen Sample Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 37: Japan 16-Year Perspective for Mpox Diagnostics by Sample - Percentage Breakdown of Value Sales for Urine Sample, Whole Blood Sample and Skin Lesion Specimen Sample for the Years 2014, 2025 & 2030
CHINA
  • Mpox Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
  • TABLE 38: China Recent Past, Current & Future Analysis for Mpox Diagnostics by Diagnostic Test - Antigen Detection Test and Molecular Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 39: China Historic Review for Mpox Diagnostics by Diagnostic Test - Antigen Detection Test and Molecular Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 40: China 16-Year Perspective for Mpox Diagnostics by Diagnostic Test - Percentage Breakdown of Value Sales for Antigen Detection Test and Molecular Test for the Years 2014, 2025 & 2030
  • TABLE 41: China Recent Past, Current & Future Analysis for Mpox Diagnostics by Sample - Urine Sample, Whole Blood Sample and Skin Lesion Specimen Sample - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 42: China Historic Review for Mpox Diagnostics by Sample - Urine Sample, Whole Blood Sample and Skin Lesion Specimen Sample Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 43: China 16-Year Perspective for Mpox Diagnostics by Sample - Percentage Breakdown of Value Sales for Urine Sample, Whole Blood Sample and Skin Lesion Specimen Sample for the Years 2014, 2025 & 2030
EUROPE
  • Mpox Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
  • TABLE 44: Europe Recent Past, Current & Future Analysis for Mpox Diagnostics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 45: Europe Historic Review for Mpox Diagnostics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 46: Europe 16-Year Perspective for Mpox Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2025 & 2030
  • TABLE 47: Europe Recent Past, Current & Future Analysis for Mpox Diagnostics by Diagnostic Test - Antigen Detection Test and Molecular Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 48: Europe Historic Review for Mpox Diagnostics by Diagnostic Test - Antigen Detection Test and Molecular Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 49: Europe 16-Year Perspective for Mpox Diagnostics by Diagnostic Test - Percentage Breakdown of Value Sales for Antigen Detection Test and Molecular Test for the Years 2014, 2025 & 2030
  • TABLE 50: Europe Recent Past, Current & Future Analysis for Mpox Diagnostics by Sample - Urine Sample, Whole Blood Sample and Skin Lesion Specimen Sample - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 51: Europe Historic Review for Mpox Diagnostics by Sample - Urine Sample, Whole Blood Sample and Skin Lesion Specimen Sample Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 52: Europe 16-Year Perspective for Mpox Diagnostics by Sample - Percentage Breakdown of Value Sales for Urine Sample, Whole Blood Sample and Skin Lesion Specimen Sample for the Years 2014, 2025 & 2030
FRANCE
  • Mpox Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
  • TABLE 53: France Recent Past, Current & Future Analysis for Mpox Diagnostics by Diagnostic Test - Antigen Detection Test and Molecular Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 54: France Historic Review for Mpox Diagnostics by Diagnostic Test - Antigen Detection Test and Molecular Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 55: France 16-Year Perspective for Mpox Diagnostics by Diagnostic Test - Percentage Breakdown of Value Sales for Antigen Detection Test and Molecular Test for the Years 2014, 2025 & 2030
  • TABLE 56: France Recent Past, Current & Future Analysis for Mpox Diagnostics by Sample - Urine Sample, Whole Blood Sample and Skin Lesion Specimen Sample - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 57: France Historic Review for Mpox Diagnostics by Sample - Urine Sample, Whole Blood Sample and Skin Lesion Specimen Sample Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 58: France 16-Year Perspective for Mpox Diagnostics by Sample - Percentage Breakdown of Value Sales for Urine Sample, Whole Blood Sample and Skin Lesion Specimen Sample for the Years 2014, 2025 & 2030
GERMANY
  • Mpox Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
  • TABLE 59: Germany Recent Past, Current & Future Analysis for Mpox Diagnostics by Diagnostic Test - Antigen Detection Test and Molecular Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 60: Germany Historic Review for Mpox Diagnostics by Diagnostic Test - Antigen Detection Test and Molecular Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 61: Germany 16-Year Perspective for Mpox Diagnostics by Diagnostic Test - Percentage Breakdown of Value Sales for Antigen Detection Test and Molecular Test for the Years 2014, 2025 & 2030
  • TABLE 62: Germany Recent Past, Current & Future Analysis for Mpox Diagnostics by Sample - Urine Sample, Whole Blood Sample and Skin Lesion Specimen Sample - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 63: Germany Historic Review for Mpox Diagnostics by Sample - Urine Sample, Whole Blood Sample and Skin Lesion Specimen Sample Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 64: Germany 16-Year Perspective for Mpox Diagnostics by Sample - Percentage Breakdown of Value Sales for Urine Sample, Whole Blood Sample and Skin Lesion Specimen Sample for the Years 2014, 2025 & 2030
ITALY
  • TABLE 65: Italy Recent Past, Current & Future Analysis for Mpox Diagnostics by Diagnostic Test - Antigen Detection Test and Molecular Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 66: Italy Historic Review for Mpox Diagnostics by Diagnostic Test - Antigen Detection Test and Molecular Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 67: Italy 16-Year Perspective for Mpox Diagnostics by Diagnostic Test - Percentage Breakdown of Value Sales for Antigen Detection Test and Molecular Test for the Years 2014, 2025 & 2030
  • TABLE 68: Italy Recent Past, Current & Future Analysis for Mpox Diagnostics by Sample - Urine Sample, Whole Blood Sample and Skin Lesion Specimen Sample - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 69: Italy Historic Review for Mpox Diagnostics by Sample - Urine Sample, Whole Blood Sample and Skin Lesion Specimen Sample Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 70: Italy 16-Year Perspective for Mpox Diagnostics by Sample - Percentage Breakdown of Value Sales for Urine Sample, Whole Blood Sample and Skin Lesion Specimen Sample for the Years 2014, 2025 & 2030
UNITED KINGDOM
  • Mpox Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
  • TABLE 71: UK Recent Past, Current & Future Analysis for Mpox Diagnostics by Diagnostic Test - Antigen Detection Test and Molecular Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 72: UK Historic Review for Mpox Diagnostics by Diagnostic Test - Antigen Detection Test and Molecular Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 73: UK 16-Year Perspective for Mpox Diagnostics by Diagnostic Test - Percentage Breakdown of Value Sales for Antigen Detection Test and Molecular Test for the Years 2014, 2025 & 2030
  • TABLE 74: UK Recent Past, Current & Future Analysis for Mpox Diagnostics by Sample - Urine Sample, Whole Blood Sample and Skin Lesion Specimen Sample - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 75: UK Historic Review for Mpox Diagnostics by Sample - Urine Sample, Whole Blood Sample and Skin Lesion Specimen Sample Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 76: UK 16-Year Perspective for Mpox Diagnostics by Sample - Percentage Breakdown of Value Sales for Urine Sample, Whole Blood Sample and Skin Lesion Specimen Sample for the Years 2014, 2025 & 2030
SPAIN
  • TABLE 77: Spain Recent Past, Current & Future Analysis for Mpox Diagnostics by Diagnostic Test - Antigen Detection Test and Molecular Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 78: Spain Historic Review for Mpox Diagnostics by Diagnostic Test - Antigen Detection Test and Molecular Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 79: Spain 16-Year Perspective for Mpox Diagnostics by Diagnostic Test - Percentage Breakdown of Value Sales for Antigen Detection Test and Molecular Test for the Years 2014, 2025 & 2030
  • TABLE 80: Spain Recent Past, Current & Future Analysis for Mpox Diagnostics by Sample - Urine Sample, Whole Blood Sample and Skin Lesion Specimen Sample - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 81: Spain Historic Review for Mpox Diagnostics by Sample - Urine Sample, Whole Blood Sample and Skin Lesion Specimen Sample Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 82: Spain 16-Year Perspective for Mpox Diagnostics by Sample - Percentage Breakdown of Value Sales for Urine Sample, Whole Blood Sample and Skin Lesion Specimen Sample for the Years 2014, 2025 & 2030
RUSSIA
  • TABLE 83: Russia Recent Past, Current & Future Analysis for Mpox Diagnostics by Diagnostic Test - Antigen Detection Test and Molecular Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 84: Russia Historic Review for Mpox Diagnostics by Diagnostic Test - Antigen Detection Test and Molecular Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 85: Russia 16-Year Perspective for Mpox Diagnostics by Diagnostic Test - Percentage Breakdown of Value Sales for Antigen Detection Test and Molecular Test for the Years 2014, 2025 & 2030
  • TABLE 86: Russia Recent Past, Current & Future Analysis for Mpox Diagnostics by Sample - Urine Sample, Whole Blood Sample and Skin Lesion Specimen Sample - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 87: Russia Historic Review for Mpox Diagnostics by Sample - Urine Sample, Whole Blood Sample and Skin Lesion Specimen Sample Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 88: Russia 16-Year Perspective for Mpox Diagnostics by Sample - Percentage Breakdown of Value Sales for Urine Sample, Whole Blood Sample and Skin Lesion Specimen Sample for the Years 2014, 2025 & 2030
REST OF EUROPE
  • TABLE 89: Rest of Europe Recent Past, Current & Future Analysis for Mpox Diagnostics by Diagnostic Test - Antigen Detection Test and Molecular Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 90: Rest of Europe Historic Review for Mpox Diagnostics by Diagnostic Test - Antigen Detection Test and Molecular Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 91: Rest of Europe 16-Year Perspective for Mpox Diagnostics by Diagnostic Test - Percentage Breakdown of Value Sales for Antigen Detection Test and Molecular Test for the Years 2014, 2025 & 2030
  • TABLE 92: Rest of Europe Recent Past, Current & Future Analysis for Mpox Diagnostics by Sample - Urine Sample, Whole Blood Sample and Skin Lesion Specimen Sample - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 93: Rest of Europe Historic Review for Mpox Diagnostics by Sample - Urine Sample, Whole Blood Sample and Skin Lesion Specimen Sample Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 94: Rest of Europe 16-Year Perspective for Mpox Diagnostics by Sample - Percentage Breakdown of Value Sales for Urine Sample, Whole Blood Sample and Skin Lesion Specimen Sample for the Years 2014, 2025 & 2030
ASIA-PACIFIC
  • Mpox Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
  • TABLE 95: Asia-Pacific Recent Past, Current & Future Analysis for Mpox Diagnostics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 96: Asia-Pacific Historic Review for Mpox Diagnostics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 97: Asia-Pacific 16-Year Perspective for Mpox Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2025 & 2030
  • TABLE 98: Asia-Pacific Recent Past, Current & Future Analysis for Mpox Diagnostics by Diagnostic Test - Antigen Detection Test and Molecular Test - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 99: Asia-Pacific Historic Review for Mpox Diagnostics by Diagnostic Test - Antigen Detection Test and Molecular Test Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 100: Asia-Pacific 16-Year Perspective for Mpox Diagnostics by Diagnostic Test - Percentage Breakdown of Value Sales for Antigen Detection Test and Molecular Test for the Years 2014, 2025 & 2030
  • TABLE 101: Asia-Pacific Recent Past, Current & Future Analysis for Mpox Diagnostics by Sample - Urine Sample, Whole Blood Sample and Skin Lesion Specimen Sample - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 102: Asia-Pacific Historic Review for Mpox Diagnostics by Sample - Urine Sample, Whole Blood Sample and Skin Lesion Specimen Sample Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 103: Asia-Pacific 16-Year Perspective for Mpox Diagnostics by Sample - Percentage Breakdown of Value Sales for Urine Sample, Whole Blood Sample and Skin Lesion Specimen Sample for the Years 2014, 2025 & 2030
AUSTRALIA
  • Mpox Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
INDIA
  • Mpox Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
SOUTH KOREAREST OF ASIA-PACIFIC
LATIN AMERICA
  • Mpox Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
ARGENTINABRAZILMEXICOREST OF LATIN AMERICA
MIDDLE EAST
  • Mpox Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
IRANISRAELSAUDI ARABIAUNITED ARAB EMIRATESREST OF MIDDLE EAST
AFRICA
  • Mpox Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
IV. COMPETITION

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Abbott Laboratories
  • ACON Biotech (Hangzhou)
  • Altona Diagnostics GmbH
  • Bio-Rad Laboratories, Inc.
  • bioMérieux
  • Cepheid (Danaher Corporation)
  • Creative Biogene Inc.
  • DiaSorin S.p.A.
  • Hologic, Inc.
  • Labcorp
  • Mayo Clinic Laboratories
  • Meridian Bioscience
  • OraSure Technologies
  • PerkinElmer Inc.
  • Pfizer (Alinity™ m MPXV assay)
  • Qiagen N.V.
  • Quidel Corporation
  • Roche Diagnostics
  • Siemens Healthineers
  • Thermo Fisher Scientific Inc.
  • Quest Diagnostics

Table Information